Researchers have found a new method to enhance the pain-relieving effects of opioids while reducing their unwanted side effects by targeting a specific protein isoform in the spine. Opioids are commonly used for chronic pain management but carry risks such as addiction and respiratory issues. This study, published in Scientific Reports, proposes a potential solution to improve pain relief and decrease addiction potential by inhibiting a Heat shock protein 90 isoform.
Dr. John Streicher from the University of Arizona Health Sciences Center led the research, investigating the role of Heat shock protein 90 in regulating opioid signaling in the spinal cord. The study revealed that inhibiting Hsp90 in the spinal cord enhanced morphine’s pain-relieving effects without the harmful side effects. By targeting individual isoforms of Hsp90, researchers were able to amplify pain relief while reducing tolerance.
The team tested selective inhibitors in mouse models and observed a significant increase in the potency of pain relief provided by morphine. These inhibitors were designed to target specific isoforms active in the spinal cord, minimizing the risk of serious side effects associated with nonselective Hsp90 inhibitors. The findings suggest that combining selective Hsp90 inhibitors with opioids could lead to lower opioid doses with improved pain relief and fewer adverse effects.
Dr. Streicher envisions a future where patients receive a combination therapy of opioids and isoform inhibitors to enhance pain relief and reduce side effects. The team is focused on developing oral formulations of these selective Hsp90 inhibitors for clinical use. This innovative approach aims to provide a safer and more effective treatment option for chronic pain without the disruptive side effects of traditional opioids.
